Compare Adaptive Biotechnologies Corp (ADPT) vs Snap On Incorporated (SNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Snap On Incorporated — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Snap On Incorporated trades at $400.71 (market cap $21.17B). The key difference: Snap On Incorporated is far larger — about 6.4× Adaptive Biotechnologies Corp's market cap, and Snap On Incorporated pays a 2.39% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SNA | |
|---|---|---|
Market Cap | $3.33B | $21.17B |
Sector | Health | Technology |
52-Week High | $22.37 | $413.62 |
52-Week Low | $10.24 | $313.01 |
Enterprise Value | $3.19B | $20.69B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Snap-on Incorporated (SNA) trades at $413.62, up 0.37% with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.6% net income margin and recently beat Q4 2025 earnings. Recent acquisitions like Diesel Laptops for $100 million demonstrate strategic growth initiatives. Analyst consensus is positive with 65% buy ratings and a $407.50 price target.
SNA presents a stable investment with consistent dividend payments and share repurchases, though Q1 2026 earnings miss and elevated valuation ratios pose near-term risks. The stock's technical overbought condition suggests potential consolidation before further upside. Long-term growth depends on successful integration of acquisitions and maintaining premium margins in the competitive tools market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
